SCHEDULE: Millennium Management Discloses Tenax Therapeutics Stake

Millennium Management and affiliated entities report a 2.1% beneficial ownership stake in Tenax Therapeutics, Inc.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported a combined beneficial ownership of 533,889 shares of Tenax Therapeutics, Inc. common stock.
• Integrated Core Strategies (US) LLC, an entity under the Millennium umbrella, holds 448,475 of these shares directly.
• The reported ownership represents approximately 2.1% of the outstanding common stock of the issuer.
• The filing is a Schedule 13G, indicating the shares are held for investment purposes without the intent to change or influence control of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of institutional holdings, reflecting standard portfolio management activity rather than a fundamental change in the company's outlook.

Positives

• Institutional interest from a major hedge fund manager, Millennium Management, provides a degree of market validation for the issuer.

Negatives

• The stake remains below the 5% threshold that typically triggers more significant activist involvement or disclosure requirements.

Risks

• The investment is subject to market volatility and the general risks associated with the biotechnology sector in which Tenax Therapeutics operates.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer, suggesting a passive investment strategy.

Industry Context

StockSavvy.ai notes that institutional filings like this are standard portfolio disclosures for large multi-strategy hedge funds and do not necessarily signal a strategic shift or impending corporate action by the issuer.

Comparison to Industry Standards

• The 2.1% stake is consistent with typical passive portfolio allocations by large institutional investment managers in small-cap biotechnology firms.

Stakeholder Impact

• Shareholders may view the presence of a major institutional investor as a positive signal of liquidity and market interest.

Next Steps

• The reporting persons will continue to monitor their investment in Tenax Therapeutics in accordance with their internal investment mandates.

Key Dates

Keywords

Tenax Therapeutics, Millennium Management, Schedule 13G, Institutional Ownership, Biotech, Equity Investment